Cargando…
Tissue factor as a new target for CAR-NK cell immunotherapy of triple-negative breast cancer
Triple-negative breast cancer (TNBC), representing ~15% of globally diagnosed breast cancer, is typically an incurable malignancy due to the lack of targetable surface targets for development of effective therapy. To address the unmet need for TNBC treatment, we recently determined that tissue facto...
Autor principal: | Hu, Zhiwei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7028910/ https://www.ncbi.nlm.nih.gov/pubmed/32071339 http://dx.doi.org/10.1038/s41598-020-59736-3 |
Ejemplares similares
-
Tissue factor-targeted immunotherapy of melanoma and triple negative breast cancer using a second generation ICON
por: Hu, Zhiwei, et al.
Publicado: (2015) -
CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
por: Pan, Kevin, et al.
Publicado: (2022) -
CAR-NK Cell: A New Paradigm in Tumor Immunotherapy
por: Marofi, Faroogh, et al.
Publicado: (2021) -
Next Generation CD44v6-Specific CAR-NK Cells Effective against Triple Negative Breast Cancer
por: Raftery, Martin J., et al.
Publicado: (2023) -
Retraction: CAR-NK Cell: a new paradigm in tumor immunotherapy
Publicado: (2023)